Biotech and Pharmaceuticals
FDA advisors recommend Eli Lilly’s Alzheimer’s drug donanemab, paving way for approval
Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval. AJ Mast | Bloomberg | Getty […]
Read More
Moderna’s combination Covid, flu vaccine is more effective than existing shots in late-stage trial
Empty bottles of Moderna’s Covid-19 vaccine. Fred Tanneau | AFP | Getty Images Moderna on Monday said its combination vaccine that targets both Covid-19 and the flu was more effective than existing standalone shots for those viruses in a late-stage trial. The biotech company is the first to release positive phase three data on a […]
Read More
FDA approves GSK’s RSV vaccine for high-risk adults ages 50 to 59, expanding shot’s reach
A view shows GlaxoSmithKline headquarters in London, Britain, January 17, 2022. Hannah Mckay | Reuters The Food and Drug Administration on Friday expanded the approval of GSK‘s respiratory syncytial virus vaccine to adults ages 50 to 59 who are at increased risk of getting severely sick from the potentially lethal virus. The shot, called Arexvy, […]
Read More
Healthy Returns: Drugmakers release promising cancer drug data – and AstraZeneca wins big
Attendees walk through the lobby at the American Society of Clinical Oncology annual meeting in Chicago. Tim Boyle | Bloomberg | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! I’m back in New York City after spending the last weekend in […]
Read More
Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
Moderna and Merck released more positive three-year data Monday on their experimental vaccine, given to patients with the most deadly form of skin cancer in combination with the therapy Keytruda. The vaccine together with Merck’s Keytruda improved survival and showed long-lasting efficacy in a midstage study in patients with a deadly form of skin cancer. […]
Read More
FDA approves Moderna’s RSV vaccine for seniors, the company’s second-ever product
The FDA has approved Moderna’s RSV vaccine for older adults. Courtesy: Moderna The Food and Drug Administration on Friday approved Moderna’s vaccine for respiratory syncytial virus for adults ages 60 and above, the company’s second-ever product to enter the U.S. market. The decision is a win for Moderna, which desperately needs another revenue source amid […]
Read More
Pfizer’s drug for advanced lung cancer shows promising long-term trial results
CHICAGO — Pfizer on Friday said its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial, which may help establish it as the new standard treatment for the condition. The company’s medicine helped patients live longer without seeing their cancer progress, and most people experienced that benefit for […]
Read More
Healthy Returns: Pfizer, Merck, J&J and more to release cancer drug data at industry conference
Attendees walk through the lobby at the American Society of Clinical Oncology annual meeting in Chicago. Tim Boyle | Bloomberg | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! This is Annika, and I’ll be on the ground at the American […]
Read More
Telehealth company Ro launches GLP-1 supply tracker to help patients navigate shortages
GLP-1 Supply Tracker from Ro. Courtesy: Ro Telehealth company Ro on Wednesday launched a new tracker to help patients find a popular class of weight loss and diabetes drugs called GLP-1s amid shortages of those treatments in the U.S. The supply tracker could be a valuable tool for many Americans scrambling to get their hands […]
Read More
This new weight loss drug ETF bets big on two of the industry’s leading players
ETF Edge This new weight loss drug ETF bets big on two of the industry’s leading players Published Mon, May 27 202412:01 PM EDT Anna Gleason@anna_gle WATCH LIVE Source
Read More